Two related updates from EnGene/Engene reinforced plans for a biologics license application in high‑risk, BCG‑unresponsive non‑muscle‑invasive bladder cancer. The companies reported additional pivotal‑cohort data for the nonviral gene therapy detalimogene voraplasmid (EG‑70), showing response durability that supports a planned BLA submission next year. Investors reacted quickly: Engene’s stock jumped on the readout, with management citing the results as validation of the amended Legend Phase II protocol and the planned regulatory path.